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Abstract
Background: As an anti-TNF agent that targets inflammatory process directly, Pentoxifylline has been investigated
for treatment of NASH in individual studies and pilot trials for years. We summarized the available information and
generating hypotheses for future research.
Data Sources: Google, Cochrane, MEDLINE, and EMBASE and the Chinese Biomedical data bases for studies
restricted to pentoxifylline treatment in humans with NAFLD in all languages until June 2010. Six studies (2
randomized, double-blind, placebo-controlled trials; 4 prospective cohort studies) extracted from 11604 references.
Results: Pentoxifylline-treated patients showed a significant decrease AST (n = 37, P = 0.01) and ALT (n = 50,
P = 0.03), but no significant effect on IL-6 (n = 36, P = 0.33) and TNF-a (n = 68, P = 0.26) compared with Placebo
or UDCA-controlled groups. Improvement in one or more histological variables was reported in two trails, only
1 study showed a reduction in of one or two points in fibrosis stage.
Limitations: The trails did not consistently report all of the outcomes of interest. Sample sizes (117 patients totally)
were small and only 2 out of 6 studies had a randomized, controlled design.
Conclusion: Pentoxifylline reduce AST and ALT levels and may improve liver histological scores in patients with
NALFD/NASH, but did not appear to affect cytokines. Large, prospective, and well-designed randomized, controlled
studies are needed to address this issue. Novel therapeutic targets for activation of inflammatory signaling
pathways by fat also merit investigation.
Introduction
Although, the pathogenesis of non-alcoholic steatohepa-
titis (NASH) is multifactorial [1-4], strong evidence of
clinical observations [5,6]and animal models[7,8] indi-
cated that inflammatory activation clearly plays a pivotal
role in the disease progression. Chronic inflammation
interplaying with increased oxidative stress, cytokine
production, direct “lipotoxicity”, and autoimmunity, is
implicated in NAFLD pathophysiology by increasing
NASH, fibrosis, and insulin resistance[9,10]. Patients
with NASH have generally significantly higher levels of
serum TNF-a and IL-6 than seen in patients with sim-
ple steatosis[11,12]. Furthermore, the expression of
cytokines is higher in those patients with more severe
NASH. Among the proinflammatory molecules, TNF-a
has been proposed to be the key link between obesity
and insulin resistance[13]. Thus, therapeutic strategies
that directly target inflammatory pathway or secondarily
alter the inflammatory process may influence both histo-
logical manifestations and systemic inflammatory state
in patients with NASH.
There is currently no FDA approved available treat-
ment for NASH. In recent years, the anti-TNF alpha
agent pentoxifylline has been considered for treatment
of NASH[14-16]. Pentoxifylline is a non-selective phos-
phodiesterase inhibitor reported to decrease TNF-a
gene transcription as well as affecting multiple steps in
the cytokine/chemokine pathway by direct or indirect
inhibition of TNF-a[17-19]. It is necessary to examine
the current state of limitation and beneficial effect of
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NAFLD or NASH and generating hypotheses for future
research. However, we could not find any systematic
reviews or meta-analyses addressing the issue. There-
fore, the purpose of the research synthesis is to sum-
marize the efficacy and safety of pentoxifylline for
NASH in terms of plasma cytokines, aminotransferase,
liver histopathology and adverse events.
Methods
Literature Sources and Search
We searched under Google, Cochrane, MEDLINE, and
EMBASE and the Chinese Biomedical data bases for stu-
dies restricted to pentoxifylline treatment in humans
with NAFLD/NASH in all languages until June 2010.
Figure 1 shows our search strategy. We also searched
the abstracts of Annual Meeting of the American and
European Association for the Study of Liver in 2009 and
2010.
A separate search filtering for meta-analysis and clini-
cal reviews yielded zero articles.
Data Extraction and Outcome Definition
For each trial, the data was gathered on the following
characteristics (Table 1.):
1. NAFLD/NASH: diagnosed on persistently elevated
aminotransferas > 1.5 times, plus liver biopsy and/or
imaging techniques;
2. Type of studies: randomized and controlled trials,
or prospective cohort studies with a control (concurrent
or historical) group;
3. Pentoxifylline was administered at any dose, dura-
tion, and given singly or in combination versus placebo
or other interventions. Co-interventions were allowed if
used equally in both intervention arms of the trial.
Disagreements were resolved through consensus.
Primary investigators were contacted if data were
incomplete.
Primary outcomes
1. Mean change from baseline of ALT, AST levels and
cytokines.
2. Histological response (number of patients with his-
tological improvement/deterioration and changes in the
Figure 1 Search strategy and results. We use the Fatty liver as the MeSH term and list all known synonyms as free-text, 11604 references
were searched totally. Combined search for all MeSH and free-text searches, 132 references were identified. Of these, we excluded 122, because
they were animal experiments, nonclinical, or clearly irrelevant. Of the remaining 10 references, 4 were excluded because they did not meet our
inclusion criteria. Finally, 6 references were identified (2 randomized trials and 4 prospective cohort studies) in the Figure 1 explained section.
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Page 2 of 6degree of fatty liver infiltration, inflammation, and fibro-
sis) based on the Brunt system or its modifications
[26,27].
Secondary outcomes
Safety and tolerability of pentoxifylline (any adverse
events as reported in trials) in patients with NAFLD or
NASH.
Assessment of Methodological Quality and Statistical
Analysis
The quality of the trials eligible for inclusion in the
review were assessed by four (Wenjun Li, Liu zheng, Liu
qing and Qu Shen) independent reviewers. Subse-
quently, other investigators and these four reviewers
confirmed whether eligible studies met the inclusion cri-
teria and independently assessed the accuracy of data
extraction. If necessary, conflict was resolved by consen-
sus of all investigators. The randomized, controlled trials
were considered as high-quality evidence, prospective
cohort studies with a concurrent control group as inter-
mediate-quality evidence, and studies with a historical
control group as low quality evidence. None of retro-
spective cohort studies was found.
Data was analyzed using the RevMan 5 provided by
The Cochrane Collaboration. The results of the primary
outcomes: mean change from baseline of ALT, AST
levels and cytokines are presented as weighted mean dif-
ferences (WMD) with 95% confidence intervals (CI). We
used a fixed-effect model with the significant level set at
P value = 0.05. Heterogeneity was explored by chi-
squared test with significance set at P value ≤ 0.10 and
the quantity of heterogeneity was measured by I
2.
Furthermore, a sensitivity analysis on the impact of the
four excluded trials was performed in both the experi-
mental and control study groups. For the secondary out-
comes (safety and tolerability of Pentoxifylline) and
histological response, we adopted available case analysis.
Results
Identification of Eligible Trials
Six studies met the specified criteria for assessment of
ALT, AST and cytokines (table 1). Only two studies
(Yin-Mei Lee and Buranawati W) are randomized dou-
ble-blind, placebo-controlled trials[20,21]. Four prospec-
tive cohort studies with control groups includes two
concurrent controls [22,23] and two historical controls
[24,25]. In addition, two trails [24,25]with historical con-
trols was not involved in the analysis of ALT, AST, and
cytokines, but histology and adverse events information
was extracted from them[24,25].
Characteristics of Patients and Interventions
Six trials included 117 patients with biopsy proven NASH
(n = 97) or NAFLD with high ALT and AST plus US or
biopsy (n = 20). Combination of studies resulted in 48
total patients for the control group(25 for Placebo plus
low-calorie diet or daily exercise, 23 for ursodeoxycholic
acid alone)and 79 patients for the pentoxifylline group
(27 pentoxifylline plus a low-calorie diet or daily exercise
and 52 pentoxifylline alone). All trials used at a dose of
800 mg to 1600 mg per day for 3-6 months. Inclusion
Criteria: Male and female patients ages 18 to 70 years;
daily alcohol intake of < 20 g; appropriate exclusion of
other liver diseases and positive testing for hepatitis B
surface antigen, hepatitis C virus antibody, or RNA of
hepatitis C virus and DNA of hepatitis B virus.
Table 1 Characteristics of 6 Trials on pentoxifylline in subjects with NAFLD
Source Methodological
quality
Diagnosis Pentoxifylline/
Control
(numbers)
Interventions Outcome
Pentoxifylline Control
LeeYin-Mei,
2008[20]
Randomized and
placebo-controled
NASH 11/9 Pentoxifylline (1200 mg/day for 12
weeks) plus low-calorie diet and daily
exercise
Placebo plus
low-calorie diet and
daily exercise
AST, ALT, IL-6,
TNF-a, adverse
events
Buranawati
W, 2007[21]
Randomized and
placebo-controled
NASH 16/16 Pentoxifylline (1200 mg/day for
12 weeks) plus low-calorie diet
Placebo plus
low-calorie diet
AST, ALT, TNF-a
Tuncer I,
2003[22]
Prospective cohort
study with concurrent
control
NAFLD 10/10 pentoxifylline (20 mg/kg/day for
24 weeks)
ursodeoxycholic acid AST, ALT
Georgescu,
EF 2007[23]
Prospective cohort
study with concurrent
control
NASH 13/13 Pentoxifylline (800 mg/day for
30 weeks)
Ursodeoxycholic acid ALT, IL-6, TNF-a,
Histology
Adams
2004[24]
Prospective cohort
study with historical
control
NASH 20 Pentoxifylline (1,600 mg/day) for
12 months
Adverse events
Satapathy
SK 2007
[25]
Prospective cohort
study with historical
control
NASH 9 Pentoxifylline (1200 mg/day for
12 months)
Histology
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Liver function response was assessed by serum activities
of AST and ALT. AST activity was evaluated in all
included trials, however, Placebo or UDCA-Controlled
studies were reported only in three trials, including two
randomized studies[20,21] and one prospective study
[22]. Pentoxifylline-treated patients showed a significant
decrease (P = 0.01) in AST activity (weighted mean dif-
ferences (WMD) -6.11 IU/L, 95% CI -10.78 to -1.44) ver-
sus control-treated patients. Heterogeneity was high, but
not statistically significant (I
2 = 30%, P = 0.24)(Figure 2).
ALT activity was evaluated in all four Placebo or
UDCA-Controlled trials[20-23]. There were significant
differences between pentoxifylline and control treatment
(P = 0.03, WMD was -6.44 IU/L, 95% CI -12.26 to
0.62). Intertrial heterogeneity was not statistically signifi-
cant (P = 0. 18) (Figure 2).
Effects on Cytokines
IL-6 and TNF-a were able to be extracted from 2 Pla-
cebo [20,21] and 1 UDCA-controlled trials [22]. Meta-
analyses of these data indicated that pentoxifylline had
no significant effect on IL-6 (P = 0.33, WMD = -1.12,
95% CI: -3.39, -1.15) and TNF-a (P =0 . 2 6 ,W M D=
-1.58, 95% CI: -4.32, -1.16). In these analyses, intertrial
heterogeneity was not statistically significant (P =0 . 8 9
and P = 0.32, respectively) (Figure 2).
Histological Response
Two trials [23,25] have assessed the histological
response that evaluated the scores of steatosis, inflam-
mation/necrosis, and fibrosis before and after treatment.
After 12 months of therapy with pentoxifylline, signifi-
cant overall improvement of liver histology was reported
in Satapathy SK’s study. Sixty seven percent of patients
had a decrease in overall grading based on Brunt’ss t a -
ging (P = 0.009). Fifty-five percent of the patients had a
reduction in their steatosis and lobular inflammation
( R R ,0 . 0 6 :9 5 %C I ,0 . 0 0t o1 . 4 3 ) .F o u ro u to ft h es i x
patients with baseline fibrosis had a reduction in their
fibrosis stage (3 had one stage reduction and 1 patient
had a two stage reduction), and another two patients
Figure 2 Overall summary of meta-analyses results of treatments of pentoxifylline for NASH. Pentoxifylline-treated patients showed
a significant decrease AST (n = 37, P = 0.01) and ALT (n = 50, P = 0.03), but no significant effect on IL-6 (n = 36, P = 0.33) and TNF-a (n = 68,
P = 0.26) compared with Placebo or UDCA-controlled groups.
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study, each histological variable before and after treat-
ment was significantly diminished from 2.231 to 1.462
for steatosis score, from 1.692 to 1.231 for the lobular
inflammation score, from 1.308 to 1.154 for hepatocyte
ballooning score and from 1.308 to 1.077 for fibrosis
score None of these scores changed significantly in the
placebo and UDCA group.
Adverse events
Among the six trials, two [20,24] provided information
on adverse events. In Adams’st r i a l[ 2 4 ] ,n i n eo f2 0
patients withdrew from the study, primarily because of
nausea, but no serious adverse events occurred. One
explanation for the significant drop out rate in the study
is probably due to a higher dose of pentoxifylline used
(1,600 mg/day). Pentoxifylline was well tolerated at a
dose of 1,200 mg/day for six months and no adverse
events and none was lost to follow-up in the trial [20]
Discussion
Pentoxifylline has been safely used for the treatment of
other medical conditions such as alcohol related liver
disease. Pentoxifylline-treated patients have a significant
mortality and hepatorenal syndrome improvements [28].
Individual studies and pilot trials of pentoxifylline in
nonalcoholic steatohepatitis have suggested that anti-
inflammatory therapy had effectively biochemical
improvement and cytokine-mediated systemic inflamma-
tion amelioration (i.e., reduced plasma TNF-a and IL-6
levels). These results serve as “proof of concept” that
pentoxifylline has efficacy in patients with nonalcoholic
steatohepatitis, but the overall benefits of this approach
have not been fully assessed quantitatively.
Improved liver aminotransferase levels are consistent
evidence from all trails in the research synthesis. Pen-
toxifylline reduced significantly ALT and AST levels in
patients with NASH compared to the placebo or UDCA
groups. Increased liver enzymes are usually thought
to be a consequence of liver injury in NAFLD, and
improvement in liver enzymes can possibly be used as
predictors of NAFLD improvement[29]. However, some
s t u d i e sh a v es h o w nt h a tas i g n i f i c a n tp r o p o r t i o no f
patients with normal ALT also had steatohepatitis and
fibrosis on liver biopsy[30-32], indicating that amino-
transferase per se cannot be used as a surrogate marker
to assess the significant potential in therapies in patients
with NASH.
Histological response was assessed only by Satapathy
SK and Georgescu EF[25,23]. Both studies evaluated the
scores of steatosis, inflammation/necrosis, and fibrosis
before and after treatment. Improvement in one or
more histological variables was noticed only in pentoxi-
fylline subgroup, but not in the UDCA subgroup in the
Georgescu EF’s study. A significant reduction in steato-
sis, ballooning and lobular inflammation was also
observed in the Satapathy SK’s study. It was interestingly
to be noted that pentoxifylline had a reduced baseline
fibrosis stage in four out of the six patients, including 3
patients had one stage and a single patient had a two
stage reduction [25]. Because fibrosis may progress in
up to one third of patients with nonalcoholic steatohe-
patitis, regardless of whether hepatic aminotransferases
improves or worsens, the antifibrotic effects of pentoxi-
fylline should surely be an important issue. The overall
methodological quality of the studies included in this
issue was relatively weak and some bias may exist. Both
are prospective studies with a historical [25] or a con-
current [23] control group, thus the true benefits may
not be as extreme as reported here.
As an anti-TNF agent, pentoxifylline may be valuable
in amelioration of cytokine-mediated systemic inflam-
mation in patients with NAS H .H o w e v e r ,t h e r ew a sn o
significant difference in the reduction of TNF-a and IL-
6 between the pentoxifylline and the control groups
[20-22]. Because of a lack of comprehensive data in
most studies, we could not reliably assess these factors.
An protocol of ongoing trial by Mary ER et al[33] is
available online, which assess the effect of pentoxifylline
on adipocyte-derived cytokines, leptin and adiponectin,
and its effect on free fatty acid levels in patients with
NASH, but we was not able to find the final report.
Despite the limitations of the studies included in this
review, it seems to suggest that pentoxifylline therapy
had a beneficial effect on liver aminotransferase levels
and histology improvements (reductions in steatosis,
inflammation, and ballooning necrosis). Large, prospec-
tive, and well-designed randomized, controlled studies are
needed to address this issue. It will probably be impor-
tant to design specific anti-inflammatory approaches for
different types and stages of NAFLD subgroups[34]. In
addition, novel ‘anti-inflammatory’ targets evolving from
basic research, such as activation of inflammatory signal-
ing pathways by fat, in particular IKK and JNK, or Foxo1,
also merit investigation[35].
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